drugset / Trial / NCT01924832
BG00012 Regional Absorption Study
Non-randomizedCrossoverOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) profile of monomethyl fumarate (MMF) following delivery of BG00012 (dimethyl fumarate, DMF) 120 mg (Part 1) and BG00012 240 mg (Part 2) to varying regions within the GI tract in healthy volunteers. The secondary objective of this study is to evaluate the safety and tolerability profile following the delivery of BG00012 120 mg (Part 1) and BG00012 240 mg (Part 2) to varying regions within the GI tract in healthy volunteers.
Timeline
- Start
- 2013-08
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dimethyl fumarate | Unknown | 120 mg | — |
| Subject | dimethyl fumarate | Unknown | 240 mg | — |
Indications
No indication recorded.